Nephrology

Long-term therapy with an angiotensin-converting enzyme (ACE) inhibitor appears to reduce urinary albumin excretion and improve lipid metabolism in patients with hypertension, research findings suggest.

Combining angiotensin II receptor blockade with angiotensin-converting enzyme (ACE) inhibition improved albuminuria and lipid profile compared with either therapy alone in patients with diabetic nephropathy.

Results of a landmark trial of 1,000.

The advanced glycation end product (AGE) inhibitor Pyridorin (pyridoxamine dihydrochloride) has potential in treating diabetic nephropathy.

Reducing systolic blood pressure is critical to slowing the progression of diabetic renal disease, researchers stated at the 35th annual meeting of the American Society of Nephrology (ASN) last week.

Elevated blood pressure and increased glucose levels are risk factors for the microvascular complications of type 2 diabetes. In contrast, blood pressure, but not glucose levels, appears to influence the risk of macrovascular complications.

Insulin resistance, a condition commonly associated with the development of type 2 diabetes, is likely a major cause of kidney disease, or nephropathy, in people with type 1 diabetes.

Anemia affects a significant proportion of people with diabetes and is a key indicator of early kidney disease.

When patients with diabetes and kidney disease were treated with Avapro the risk of progression of their nephropathy or death was 20 percent lower.

“Kidney disease is an under-recognized, under-diagnosed and under-treated” Checking for urine microalbumin and protein are essential in catching it early.